Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2/3 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Venous Thrombosis 1Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Nadroparin × Clear all
NCT00312013 2017-03-23

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

GlaxoSmithKline

Phase 3 Completed
503 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Venous Thrombosis

NCT00951574 2012-02-01

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Italfarmaco

Phase 3 Completed
1,166 enrolled

Neoplasm Metastasis, Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡